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double-labelled peptidic substrates with an
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Hans H. Gorris*
The proteolytic activity of renin is a key element in the regulation of blood pressure and a main target for
inhibitor design. Currently, the activity of renin and its inhibitors is mainly analyzed using
radioimmunoassays or FRET-substrates, which both have their limitations. Here, a novel kinetic assay is
presented that combines the advantages of a homogeneous proteolytic reaction and a robust
heterogeneous detection in a sandwich immunoassay format. The proteolysis in solution is not
inﬂuenced by surface interactions and yields accurate kinetic values, while the speciﬁc detection of the
cleavage products on a microtiter plate strongly reduces interference by concomitant substances and
allows for a self-referenced signal readout. A new enzyme kinetic scheme for the inhibition of renin has
been developed and validated by using the model inhibitor pepstatin. This kinetic analysis is amenable
to parallelization for large-scale inhibitor screening. Furthermore, it can be easily adapted to inhibitors
of other medically important proteases.Introduction
Renin is a monomeric 37 kDa aspartyl-protease that initiates
the renin–angiotensin system (RAS). This protease cascade
regulates homeostatic processes, such as blood pressure and
uid volume, but is also involved in the development and
progression of brotic and hypertrophic diseases.1 Renin is
released from the kidneys into the circulation and specically
cleaves the N-terminal part of the 50 kDa glycoprotein angio-
tensinogen. The N-terminal decapeptide angiotensin I is further
processed by angiotensin-converting enzyme (ACE) to the
octapeptide angiotensin II. By binding to the AT1 receptor,
angiotensin II induces vasoconstriction as well as renal sodium
and water retention, which increase blood pressure. In partic-
ular, the central role in the regulation of blood pressure has
urged the development of drugs that inhibit RAS compounds.
Renin, the rst and rate-limiting step of the RAS, has long been
considered as the preferable target for inhibition.2 Until
recently, however, only ACE inhibitors or AT1 receptor blockers
were available for the treatment of hypertension that are
implicated in adverse eﬀects.3 For example, ACE inhibitors also
inhibit the proteolysis of bradykinin, which may result in cough
and angioedema, and angiotensin II can still be produced by
other proteases. The action of angiotensin II, on the other hand,nd Biosensors, University of Regensburg,
ans-Heiner.Gorris@ur.de; Fax: +49-941-
(ESI) available: Analysis of renin in
/c3an36508e
9cannot be completely suppressed by AT1 blockers as it can bind
to diﬀerent receptor subtypes. Consequently, when the rst
orally available renin inhibitor aliskiren was approved in 2007,
it was considered an important hallmark in the more than 100
year-old history of renin and sparked renewed interest in its
activity and inhibition.4
Haber et al.5 introduced the rst reliable radioimmunoassay
for measuring the activity of plasma renin in 1969 that – in
diﬀerent variations – is still widely used today.6 For this
competitive immunoassay, the product angiotensin I is
captured by an immobilized antibody. Then, the radiolabeled
angiotensin I is added, which binds to the remaining free sites
of the capture antibody and can be measured with a scintilla-
tion counter. To avoid radioactive materials other – mainly
homogeneous – assay formats have been developed, e.g. based
on HPLC-electrospray-tandem mass spectrometry,7 uorogenic
substrates8–10 or FRET.11–13 For uorogenic substrates, however,
a uorophore must be placed next to the cleavage site, and
FRET substrates are only quenched eﬃciently if the distance
between the donor and acceptor is typically in the range of 2 to
6 nm.14 In particular, peptidic substrates of renin that are
derived from the large protein sequence of angiotensinogen
require long sequences of at least eight amino acids to show
signicant hydrolysis rates,15 and considerable eﬀort has been
devoted to identifying good FRET substrates.13
We have recently introduced a new stability test for peptides
that imposes no restriction on the length of the amino acid
sequence and combines the advantages of homogeneous and
heterogeneous assay formats.16 First, double-labelled peptides are
subjected to proteolytic degradation in solution (homogeneousThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinephase). The peptide is then transferred and immobilized on a
microtiter plate via its N-terminal label.17 If the peptide has
not been cleaved, the C-terminal label binds to an enzyme-
amplied detection system. If the peptide has been cleaved, by
contrast, it does not contain the C-terminal label and no signal is
observed. The ratio of cleaved to uncleaved peptide denes the
stability of the peptide in a biological sample. Here, we employ
this detection scheme to accurately determine the proteolytic
activity of renin in parallel, and demonstrate how it can be used to
elucidate renin–inhibitor interactions with the model inhibitor
pepstatin.18–20Experimental
Buﬀers and reagents
L(ite)-PBS: 10 mM sodium phosphate, pH 7.0, 10 mM NaCl;
D(ulbecco's)-PBS: 2.7 mM KCl, 1.5 mM KH2PO4, 136 mM NaCl,
8.1 mM Na2HPO4, pH 7.3; maleate buﬀer: 50 mM maleic acid,
33.5 mM Tris, 10 mM EDTA, adjusted to pH 6.0 with NaOH. The
monoclonal anti-2,4-D antibody clone E2/G2 was a kind gi
from Milan Fra´nek.21 Recombinant human renin (50 mg ml1 in
50 mM aqueous 3-(N-morpholino)propanesulfonic acid, pH 7.0)
was purchased from Anaspec (http://www.anaspec.com);
horseradish peroxidase-labelled streptavidin (SA-HRP, 1 mg
ml1 in 50 mM NaHCO3, pH 8.3) from Vector Laboratories
(http://www.vectorlabs.com); pepstatin from Roche (http://
www.roche.de); and 3,30,5,50-tetramethylbenzidine (1-Step
Ultra TMB-ELISA) from Pierce Biotechnology (http://
www.piercenet.com).Peptide synthesis of renin substrates
Peptides were synthesized on a tentagel amide resin (0.24 mmol
g1; Intavis, http://www.intavis.com) at room temperature (rt)
using standard uorenylmethoxycarbonyl (Fmoc) protection
chemistry and an automated multiple peptide synthesizer
(MultiPep RS, Intavis). First, 1.3 g of the resin was swollen in 50
ml of a solvent mixture (7 : 3, v/v) of dichloromethane and
dimethylformamide (DMF). Then, 3 mmol of the resin were
transferred to wells of a lter bottom microtiter plate (Intavis,
96 well reaction plate, 2–5 mmol) and washed three times with
300 ml of DMF. The resin was Fmoc-deprotected two times for 5
min with 170 ml of 20% (v/v) piperidine in DMF, and washed ten
times with 250 ml of DMF. A solvent mixture of 24 ml of 0.6 M
Fmoc-amino acid (Iris Biotech, http://www.iris-biotech.de) in
DMF, 8 ml of 4 M 4-methylmorpholine in DMF, and 23 ml of
0.6 M 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hex-
auorophosphate (Iiris Biotech) in DMF was applied to the
resin two times for 30 min. The resin was washed three times
with 300 ml of DMF, incubated for 5 min with 120 ml of 5% (v/v)
acetic anhydride in DMF to acetylate unreacted terminal amino
groups, and washed six times with 250 ml of DMF. The synthesis
cycles were repeated to assemble individual peptides in each
well. Aer a nal deprotection step, the resin was washed ten
times with 250 ml of DMF. Terminal amino groups of the
peptides were acetylated by adding two times 120 ml of 5% acetic
anhydride (v/v) in DMF for 5 min. The resin was washed eightThis journal is ª The Royal Society of Chemistry 2013times with 250 ml of DMF, and six times with 150 ml of
dichloromethane. Aer extracting for 5 min, the resin was dried
in vacuo for 12 h. The resin was incubated for 10 min, 30 min
and 90 min with 100 ml of a solvent mixture (v/v) of 92.5% tri-
uoroacetic acid, 5% triisobutylsilane, and 2.5% water to
release the peptides into solution, which was then collected in a
96-well plate (MegaBlock, Sarstedt, http://www.sarstedt.com)
and dried in vacuo. The peptides were incubated with 1250 ml of
cold methyl tert-butyl ether for 12 h, the supernatants were
removed, and the peptides were dried in vacuo. A stock solution
of 3 mM peptide in DMF was prepared and analyzed by reversed
phase HPLC (HP Agilent 1100, http://www.chem.agilent.com)/
electrospray ionization mass spectrometry (ThermoQuest Fin-
nigan TSQ 7000, Finnigan, Bremen, Germany). For further
experiments, the peptide was rst diluted to 100 mM in ethanol
and then to 1 mM in L-PBS  0.005% (w/v) Tween 20.
Capture ELISA
High-bind 96-well microtiter plates (Corning, http://
www.corning.com) were coated overnight at 4 C with 75 ml
per well of 150 ng ml1 anti-2,4-D antibody in L-PBS. Aer three
washing steps using 300 ml of D-PBS 0.05% (w/v) Tween 20 (D-
PBST), the plates were blocked for 3–4 h at rt with 250 ml of 1%
(w/v) casein in D-PBS, and again washed four times with
D-PBST. Peptides 1, 2 and 3 were serially diluted in 50 ml of
maleate buﬀer  0.005% (w/v) Tween 20. Aer 2 h and 30 min,
the plates were washed four times with D-PBST and incubated
for 60 min at rt using 75 ml of 1 mg ml1 SA-HRP in 1% (w/v)
casein in D-PBS. The plates were washed six times with D-PBST
and developed with 75 ml of tetramethylbenzidine. The colour
development was terminated aer 30 min by adding 125 ml of 1
MH2SO4, and the absorption wasmeasured at l¼ 450 nm using
a microtiter plate reader. The soware GraphPad Prism 5 was
used to t the data curves.
Renin assay
The proteolytic reaction of renin was carried out in a 96-well
polypropylene microtiter plate (Corning, http://
www.corning.com). Either a dened concentration of human
renin or murine plasma samples were serially diluted in 50 ml
per well of 10 nM peptide in maleate buﬀer  0.005% (w/v)
Tween 20. For inhibition studies, constant concentrations of
pepstatin were added to the peptide solution. The sealed
microtiter plate was incubated for either 90 min or 20 h at 37 C.
The proteolytic reaction was terminated by adding 50 ml of a 2
mM pepstatin solution and incubating on ice for 10 min. From
each cavity, 75 ml of the peptide solution was transferred to a
high-bind 96-well microtiter plate which beforehand had been
coated with 75 ml of 150 ng ml1 anti-2,4-D antibody, washed
and blocked as described above. Aer 2 h and 30 min at rt, the
plate was washed four times with D-PBST, and incubated for 60
min at rt using 75 ml of 1 mg ml1 of horseradish peroxidase-
labelled streptavidin in 1% (w/v) casein in D-PBS. The plates
were washed six times with D-PBST and developed with 75 ml of
tetramethylbenzidine. The colour development was terminated
aer 30 min by adding 125 ml of 1 M H2SO4, and the absorptionAnalyst, 2013, 138, 2104–2109 | 2105
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View Article Onlinewas measured at l ¼ 450 nm with a microtiter plate reader. The
soware GraphPad Prism 5 was used to t the data curves.Results and discussion
Design of renin substrates
The optimal design of a peptidic substrate for the protease renin
foremost depends on a good cleavage site that is available from
the N-terminal amino acid sequence of angiotensinogen.13 We
chose the rst 15 N-terminal amino acids of angiotensinogen
(DRVYIHPFHLVIHNE) for detecting the activity of human renin.
It should be noted that there is no photophysical constraint on
the length of the sequence, in contrast to e.g. the length of FRET
substrates. Furthermore, the peptide must be labelled at the
N- and C-terminus for detection in a sandwich ELISA format: one
label is required for immobilizing the peptide on the surface of a
microtiter plate and the other label for binding a detection
system. The hapten 2,4-dichlorophenoxyacetic acid (2,4-D) in
combination with aminoundecanoic acid is an optimal
N-terminal label for binding a peptide to amicrotiter plate coated
with an anti-2,4-D-antibody (clone E2/G2).17,22 Biotin is chosen as
the C-terminal label due to its extremely high binding aﬃnity to
streptavidin.23 The detection system consists of a streptavidin–
horseradish peroxidase conjugate that catalyzes a chromogenic
reaction.
Positively charged peptides may bind non-specically to
microtiter plates, which can be attributed to cation–p interac-
tions between the side chains of lysine, arginine or histidine and
polystyrene.16,24 This non-specic binding, however, must be
avoided to be able to distinguish between cleaved and intact
peptides aer a proteolytic reaction. As the peptidic renin
substrate (Peptide 1) has a net charge of +3, peptides anked by
either PEG (Peptide 2) or both PEG and D-glutamate (Peptide 3)
were synthesized to compensate for non-specic binding of the
core region (Fig. 1A). The peptides were diluted serially
on antibody-coated as well as uncoated microtiter plates
(Fig. 1B–D) (a) to optimize the concentration of the coating
antibody and (b) to nd the peptide concentration that yields aFig. 1 (A) Peptide 1 consists of the N-terminal label 2,4-dichlorophenoxyacetic acid
including the cleavage site for renin, a short polyethylene glycol (PEG), and the C-t
Peptide 3 by both D-glutamic acid (D-Glu) and a short PEG. (B–D) Peptides are diluted
coated with 150 ng ml1 of anti-2,4-D-antibody (full circles). (D) The optical densiti
non-speciﬁc binding (solid squares) are ﬁtted to a logistic function: ODc ¼ (ODmax 
0.95), the background (ODbg ¼ 0.01), the half eﬀective concentration (EC50 ¼ 1.0 nM
deviation of at least three measurements.
2106 | Analyst, 2013, 138, 2104–2109high antibody-mediated signal without non-specic surface
binding. Non-specic binding to microtiter plates is evident at
high peptide concentrations and increases the signal intensity in
addition to antibody-mediated binding. Peptide 3 (Fig. 1D)
displays the lowest non-specic binding, which can be well
separated from antibody-mediated binding. In general, peptide
concentrations below 5 nM did not result in non-specic
binding. Thus, a constant peptide concentration of 5 nM was
employed in the sandwich ELISA for detecting the proteolytic
activity of renin.Renin assay
Both renin and the peptidic substrate are free in solution
(homogeneous assay) to avoid surface eﬀects on the enzyme
reaction. The proteolytic activity of renin separates the N- and C-
terminal label of the peptide. With increasing renin activity in a
sample, the ratio between intact and cleaved peptides
decreases. Serial dilutions of renin in dened peptide solutions
(10 nM) lead from samples that contain only cleaved peptides
over mixtures to samples that contain only intact peptides. Aer
transferring each sample to an antibody-coated microtiter plate,
both cleaved and intact peptides are immobilized proportion-
ally via their N-terminal 2,4-D label. An ELISA-signal, however,
is generated only by the biotin label of the intact peptide. As the
signal intensities in a well are aﬀected by the experimental – in
particular coating – conditions, the intact peptide was used as a
reference signal to obtain ratiometric measurements that are
essentially independent of absolute signal intensities.25,26 The
ratio of the signal aer renin incubation to the reference signal
thus denes the degree of proteolytic degradation.
For data analysis according to Michaelis–Menten kinetics,
usually steady-state conditions are given by an excess of
substrate over enzyme ([S][ [E]). Due to the very high sensi-
tivity of peptide detection using the sandwich ELISA, peptide
concentrations lower than 10 nM can be detected. The renin
concentration, by contrast, must be high enough for a detect-
able turnover (up to 12.5 nM, Fig. 2), which seems to violate the(2,4-D), aminoundecanoic acid (Aun), the core peptide sequence (15 amino acids)
erminal label biotin. The sequence of Peptide 2 is extended by a short PEG, and
serially on either an uncoated microtiter plate (empty circles) or a microtiter plate
es (ODc) obtained at diﬀerent peptide concentrations (c) without interference by
ODbg)/(1 + (c/EC50)^s) + ODbg, which yields the highest optical density (ODmax ¼
), and the slope at the inﬂection point (s ¼ 0.86). Error bars indicate the standard
This journal is ª The Royal Society of Chemistry 2013
Fig. 2 Proteolytic degradation of Peptide 1 (A), Peptide 2 (B) and Peptide 3 (C
and D) by human renin. Dilution series of renin were applied to the peptides in
solution (10 nM) for either 90 min (A–C) or 20 h (D) at 37 C. After terminating the
enzyme reaction by a two-fold concentrated inhibitor solution, the peptides (5
nM) were detected using a sandwich ELISA. The data (four measurements; the
error bars indicate the standard deviation) were ﬁtted to eqn (2). The strongest
signal response of OD450nm to varying renin concentrations is observed in the test-
midpoint, which is used to calculate kcat/KM.
Table 1 Renin assays based on synthetic substrates
Method Sequence motif
kcat/KM
(M1 s1)
ELISA-based renin assaya DRVYIHPFHL|VIHNE(15 aa) 308 000
Radioimmunoassay37 DRVYIHPFHL|VIHN (14 aa) 250 000
HPLC38 DRVYIHPFHL|VIHS (14 aa) 180 000b
FRET(DNP/Amp)13 DRVYIHPFHL|VIH (13 aa) 181 000
FRET(DNP/Amp)13 KHPFHL|VIH (9 aa) 352 000
FRET(EDANS/DABCYL)c,13 IHPFHL|VIHT (10 aa) 268 000
a Present study. b Estimated from KM ¼ 8.4 mM and Vmax ¼ 11 mmol
angiotensin I made per h per mg renin.38 c Commercial substrate.
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View Article Onlinesteady-state approximation. Segel pointed out, however, that the
steady-state approximation also holds with [S] + KM[ [E].27 As
KM of good peptidic renin substrates lies in the range of 0.5 to
1 mM,13 the steady-state approximation is valid for the new renin
assay.
The integrated Michaelis–Menten equation describes the
progress of the enzyme reaction:
KM  ln ½S0½S þ ½S0  ½S ¼ kcat  ½E  t (1)
where [S] is the substrate concentration (0 indicates the initial
substrate concentration/intact peptide), [E] the enzyme
concentration, t the time, and KM and kcat are the kinetic
constants. [S] can be replaced by the background corrected
optical density (OD) of the ELISA measurement and the refer-
ence signal [S]0 is given by ODmax.
Under the conditions used for the renin assay ([S]  KM),
eqn (1) reduces to a pseudo-rst order reaction:
OD ¼ ODmax ODbg e

t½E
kcat
KM

þODbg (2)
which yields the second order rate constant kcat/KM as a
regression parameter. kcat/KM is the most accurate kinetic
constant for characterizing a protease's specicity for a
substrate.28 While it is common to measure the reaction prog-
ress aer various time intervals, eqn (2) also allows for varying
the enzyme concentration at constant incubation times. This
approach is more favourable when carrying out kinetic experi-
ments in a highly parallel way using a sandwich ELISA.16
Incubating Peptide 1, 2 and 3 for 90min with 10 nM to 10 pM
of human renin resulted in a continuous transition in OD from
completely degraded peptides (ODbg) to intact peptides (ODmax)
that was used to calculate kcat/KM according to eqn (2) (Fig. 2).
Structural modications in the anking region of the 15 aminoThis journal is ª The Royal Society of Chemistry 2013acid-long core peptide (see Fig. 1A) had some eﬀect on kcat/KM.
Peptide 3, which was the best candidate with respect to low non-
specic binding, also yielded the highest kcat/KM of 308 000 M
1
s1 (Fig. 2B). Aer a prolonged incubation time of 20 h,
however, this value appeared to decrease to 159 000 M1 s1
(Fig. 2D), which can be attributed to a loss of enzyme activity.
Using a relatively short and constant incubation time of 90 min
instead of time series, thus, is a simple way to avoid a loss of
enzyme activity.
The double-labelled renin substrates employed in the ELISA-
based assay yielded comparable results for kcat/KM as FRET-based
substrates of similar length (Table 1). Paschalidou et al.13 char-
acterized the inuence of the peptide length in FRET-based
substrates on kcat/KM in detail. When they extended the peptide
sequence one amino acid at a time, kcat/KM increased successively
but an optimum was not reached with a length of 13 amino acids
(181 000M1 s1). As the quenching eﬃciency decreases with the
sixth power of the distance between the donor and acceptor, the
FRET substrate comprising 13 amino acids resulted in a signal to
background ratio of only ve and thus was classied as rather
insensitive. Longer peptides are in general not practical. To
circumvent this length limitation, the amino acid sequence was
modied in search of optimal shorter substrates (Table 1).Analysis of plasma samples
As the new protease assay is robust even in raw intestinal
uids,16,29 it was applied to analyzing the activity of renin in raw
murine plasma. Experimental details are given in the ESI.†Mice
were treated intraperitoneally with isoproterenol to stimulate
the production of renin, and one hour later plasma from treated
and untreated mice was collected.6 Using a commercial radio-
immunoassay and angiotensinogen as a substrate, it was shown
that the renin activity was 100-fold higher in treated than in
untreated mice. In the ELISA-based renin assay, however, both
plasma samples showed the same activity on murine peptidic
substrates, which can be explained by the nonspecic activity of
other proteases than renin in plasma. The three-dimensional
conformation of the large (50 kDa) natural substrate angio-
tensinogen protects the cleavage site from various other prote-
ases present in blood. Here, we have presented experimental
evidence for the non-specic activity of plasma on synthetic
renin substrates that has been described only marginally in
previous literature reports.15,30Analyst, 2013, 138, 2104–2109 | 2107
Fig. 3 Inhibition of human renin by pepstatin. (A) Renin was diluted serially on
the peptide without inhibitor (black circles), and in the presence of 1 mM (blue
squares), 2.5 mM (green diamonds) and 10 mM (red triangles) of pepstatin. (B) The
rate constants were normalized according to eqn (5), and the slope of the linear
regression yielded Ki¼ 2.7 mM (r2¼ 0.9994). Data points represent the mean of at
least three measurements.
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View Article OnlineInhibition of renin
Due to the key role of renin in the regulation of blood pressure,
it is essential to identify potent renin inhibitors.4,31,32 The renin
assay can be adapted to inhibitor screening by diluting renin
serially on a xed mixture of peptidic substrate and competitive
inhibitor, incubating for 90 min at 37 C, and detecting the
proteolytic reaction on an antibody-coated microtiter plate. The
inhibition of renin can then be analyzed based on the inte-
grated Michaelis–Menten equation for competitive inhibition:
KM 

1þ ½I
Ki

 ln ½S0½S þ½S0 ½S ¼ kcat  ½E  t (3)
where [I] is the inhibitor concentration and Ki is the inhibition
constant. Under pseudo-rst order reaction conditions ([S] KM),
the rate constant k0 ¼ [E] kcat/KM of the uninhibited reaction in
eqn (2) changes to the rate constant ki of the inhibited reaction:
ki ¼ ½E kcat
KM

1þ ½I
Ki
 (4)
Using various inhibitor concentrations and standardizing to
the uninhibited reaction (k0) yields a linear equation:
k0
ki
¼ 1þ ½I
Ki
(5)
Starting from a y-intercept of 1 without inhibitor, k0/ki
increases linearly with the inhibitor concentration, and Ki can
be obtained from the slope.
The microbial peptide pepstatin (isovaleryl-L-valyl-L-valyl-4-
amino-3-hydroxy-6-methylheptanoyl-L-alanyl-4-amino-3-hydroxy-
6-methylheptanoic acid)33 is a competitive inhibitor of renin18,34
and other aspartyl proteases.35 Pepstatin is a well-characterized
transition state analog of aspartyl protease substrates that
constitutes a good model system for the inhibition of renin.
Using the ELISA-based renin assay, a Ki of 2.7 mM pepstatin was
calculated for the inhibition of human renin (Fig. 3). The
excellent linearity of k0/ki with the inhibitor concentration
shows that it is suﬃcient to use only a single inhibitor
concentration to determine Ki accurately if kcat/KM of the
uninhibited reaction is known. Literature reports of Ki are also
in the lower micromolar range, but vary because the inhibition
by pepstatin is inuenced by the pH, the substrate, and other2108 | Analyst, 2013, 138, 2104–2109experimental conditions. For example, when angiotensinogen
was used as the substrate, the Ki was 1.4 mM pepstatin at pH 5.7,
but 16 mM at pH 7.4.19 When a synthetic tetradecapeptidic
substrate was used at pH 6.5, a Ki of 15 mM was calculated.20
Conclusions
The variations in the determination of Ki among literature
values highlight the need for well-dened experimental condi-
tions to obtain comparable results from inhibitor screening.
Here, we have presented a simple and robust kinetic analysis
that yields excellent kinetic values for the activity of renin and
its inhibitors. In contrast to the widely used FRET-substrates,
the new renin analysis is not inuenced by the absolute signal
intensity, optical interference in renin samples, and the length
of the renin substrates. The new kinetic analysis can be easily
adapted to inhibitor screening of other medically important
proteases. For example, the renin–pepstatin interaction can
serve as a model for the inhibition of the aspartyl-protease from
the human immunodeciency virus (HIV),36 which is a major
drug target for the treatment of HIV.
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AT1 receptor Angiotensin II receptor subtype-1;
Aun Aminoundecanoic acid;
2,4-D 2,4-dichlorophenoxyacetic acid;
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